Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06519656 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Efficacy of Mazdutide for Treating PCOS

StatusCompleted
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date changed from estimate of Dec 31, 2025 to Sep 1, 2026 Show 6 more changesShow less
    • Trial completed
    • Final enrollment: 43 participants (planned 50)
    • Study completion date changed from estimate of Jun 30, 2026 to Sep 18, 2026
    • Secondary endpoints: details revised at 2 of 7 entries
    • Site details revised
    • Eligibility criteria shortened, about 2 words
  2. Start date changed from estimate of Jul 20, 2024 to Oct 21, 2024v2
  3. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical trial is to learn the efficacy of Mazdutide in treating obese female adults diagnosed with polycystic ovary syndrome (PCOS). The main question it aims to answer is: Does Mazdutide lower the free androgen index (FAI) in obese female adults with PCOS? Participants will take Mazdutide once every week for 24 weeks and visit the clinic once every 4 weeks for checkups and tests.
Trial Details
NCT Number NCT06519656
Lead Sponsor Shanghai Zhongshan Hospital
Conditions
(from sponsor)		 Polycystic Ovary Syndrome
Related terms Polycystic Ovary Syndrome
Enrollment 43 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov